Immunogenicity of an <i>Escherichia coli</i>-Produced Recombinant 9-Valent Human Papillomavirus Vaccine in Mice and Rats
<b>Background:</b> Prophylactic human papillomavirus (HPV) vaccines are crucial for preventing HPV-related cancers. This study aimed to preclinically evaluate a novel recombinant 9-valent HPV vaccine produced in <i>Escherichia coli</i> (<i>E. coli</i>), which targets HPV types 6, 11, 16, 18, 31, 33,...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI AG
2026-05-01
|
| Edice: | Vaccines |
| Témata: | |
| On-line přístup: | https://www.mdpi.com/2076-393X/14/5/407 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
